INTRODUCTION: Laboratory and clinical data have implicated endotoxin as an important factor in the inflammatory response to cardiopulmonary bypass. We assessed the effects of the administration of bovine intestinal alkaline phosphatase (bIAP), an endotoxin detoxifier, on alkaline phosphatase levels in patients undergoing coronary artery bypass grafting. METHODS: A total of 63 patients undergoing coronary artery bypass grafting were enrolled and prospectively randomized. Bovine intestinal alkaline phosphatase (n=32) or placebo (n=31) was administered as an intravenous bolus followed by continuous infusion for 36 hours. The primary endpoint was to evaluate alkaline phosphatase levels in both groups and to find out if administration of bIAP to patients undergoing CABG would lead to endogenous alkaline phosphatase release. RESULTS: No significant adverse effects were identified in either group. In all the 32 patients of the bIAP-treated group, we found an initial rise of plasma alkaline phosphatase levels due to bolus administration (464.27±176.17 IU/L). A significant increase of plasma alkaline phosphatase at 4-6 hours postoperatively was observed (354.97±95.00 IU/L) as well. Using LHA inhibition, it was shown that this second peak was caused by the generation of tissue non specific alkaline phosphatase (TNSALP-type alkaline phosphatase). CONCLUSIONS:Intravenous bolus administration plus 8 hours continuous infusion of alkaline phosphatase in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass results in endogenous alkaline phosphatase release. This endogenous alkaline phosphatase may play a role in the immune defense system.
RCT Entities:
INTRODUCTION: Laboratory and clinical data have implicated endotoxin as an important factor in the inflammatory response to cardiopulmonary bypass. We assessed the effects of the administration of bovine intestinal alkaline phosphatase (bIAP), an endotoxin detoxifier, on alkaline phosphatase levels in patients undergoing coronary artery bypass grafting. METHODS: A total of 63 patients undergoing coronary artery bypass grafting were enrolled and prospectively randomized. Bovine intestinal alkaline phosphatase (n=32) or placebo (n=31) was administered as an intravenous bolus followed by continuous infusion for 36 hours. The primary endpoint was to evaluate alkaline phosphatase levels in both groups and to find out if administration of bIAP to patients undergoing CABG would lead to endogenous alkaline phosphatase release. RESULTS: No significant adverse effects were identified in either group. In all the 32 patients of the bIAP-treated group, we found an initial rise of plasma alkaline phosphatase levels due to bolus administration (464.27±176.17 IU/L). A significant increase of plasma alkaline phosphatase at 4-6 hours postoperatively was observed (354.97±95.00 IU/L) as well. Using LHA inhibition, it was shown that this second peak was caused by the generation of tissue non specific alkaline phosphatase (TNSALP-type alkaline phosphatase). CONCLUSIONS: Intravenous bolus administration plus 8 hours continuous infusion of alkaline phosphatase in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass results in endogenous alkaline phosphatase release. This endogenous alkaline phosphatase may play a role in the immune defense system.
Authors: Florian Kühn; Ruifeng Duan; Matthias Ilmer; Ulrich Wirth; Fatemeh Adiliaghdam; Tobias S Schiergens; Joachim Andrassy; Alexandr V Bazhin; Jens Werner Journal: Visc Med Date: 2021-04-29
Authors: Kevin M Riggle; Rebecca M Rentea; Scott R Welak; Kirkwood A Pritchard; Keith T Oldham; David M Gourlay Journal: J Surg Res Date: 2012-11-08 Impact factor: 2.192
Authors: Jesse A Davidson; Tracy T Urban; Christine Baird; Suhong Tong; Alan Woodruff; Mark Twite; James Jaggers; Eric A F Simões; Paul Wischmeyer Journal: J Pediatr Date: 2017-11 Impact factor: 4.406
Authors: Jesse A Davidson; Tracy T Urban; Suhong Tong; Aline Maddux; Gerald Hill; Benjamin S Frank; John D Watson; James Jaggers; Eric A F Simões; Paul Wischmeyer Journal: Shock Date: 2019-03 Impact factor: 3.454
Authors: Thomas Poschner; Anne-Kristin Schaefer; Doris Hutschala; Georg Goliasch; Julia Riebandt; Klaus Distelmaier; Martin H Bernardi; Martin Andreas; Ruud Brands; Tandis Aref; Günther Laufer; Dominik Wiedemann Journal: Biomolecules Date: 2021-05-17
Authors: Alva Presbitero; Emiliano Mancini; Ruud Brands; Valeria V Krzhizhanovskaya; Peter M A Sloot Journal: Front Immunol Date: 2018-10-11 Impact factor: 7.561